Don’t miss – Page 204 – Endpoints News

SIGN UP

Scott Gottlieb tempts the FDA's fiercest critics with his leap onto Pfizer's board of directors

4 years ago

Turned back at the FDA, ImmunoGen is axing 220 staffers, selling programs and hunkering down for a new PhIII gamble

4 years ago

AstraZeneca challenges Roche on frontline SCLC after seizing an interim win — and Merck may not be far behind

4 years ago

Top analyst finds a silver lining in AbbVie’s $63B Allergan buyout — but there’s a catch

4 years ago

After raising $158M, this upstart's founders have star backers and plans to break new ground in gene therapy

4 years ago

AbbVie's $63B buyout spotlights the return of major M&A deals — despite the backlash

4 years ago

AbbVie seals $63B deal to buy a troubled Allergan — spelling out $1B in R&D cuts

4 years ago

In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later

4 years ago

Why would the FDA approve another controversial drug to spur a woman’s libido with these data? And why no expert panel review?

4 years ago

Which top 10 big pharmas have the most to gain — or lose — over the next 5 years?

4 years ago

HIV, pneumococcal — and what? Merck's unexpected pipeline highlight excites a little biotech

4 years ago

Who’s next in line to succeed Ken Frazier as CEO of the Keytruda-blessed Merck?

4 years ago

Sanofi's John Reed continues to reorganize R&D, cutting 466 jobs while boosting cancer, gene therapy research

4 years ago

A new number 1 drug? Keytruda tapped to top the 10 biggest blockbusters on the world stage by 2024

4 years ago

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

4 years ago

After watching its share price soar on a Bloomberg report and heated rumors, Biohaven stock takes a billion-dollar bath

4 years ago

The top 10 blockbuster drugs in the late-stage pipeline — Evaluate adds 6 new therapies to heavy-hitter list

4 years ago

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

4 years ago

Pfizer CEO Albert Bourla is back in the M&A game, but why is he paying $11.4B for Array?

4 years ago

Global Blood Therapeutics poised to submit application for accelerated approval, with new pivotal data on its sickle cell disease drug

4 years ago

Gene therapies seize the top of the list of the most expensive drugs on the planet — and that trend has just begun

4 years ago

As another antibiotics biotech sinks into a crisis, warnings of a sector ‘collapse’

4 years ago

Bain’s biotech team has created a $1B-plus fund — with an eye to more Big Pharma spinouts

4 years ago

Searching for the next blockbuster to follow Darzalex, J&J finds a $150M anti-CD38 drug from partner Genmab

4 years ago

First page Previous page 201 202 203204205 206 207 Next page Last page